0130 GMT - IHH Healthcare's earnings may stay resilient in 2H, given improvements in inpatient volumes, Affin Hwang IB analyst Andrew Lim says in a note. The healthcare provider looks well on track to achieve 29% EPS growth for 2024, supported by a low 2023 base and stronger contributions from Malaysia, Turkey and India, he reckons. Ringgit appreciation could have minimal impact on IHH, as conservative estimates for SGD, which makes up nearly 50% of its profit before tax were already factored in, he adds. IHH plans to add about 4,000 beds over the next four years, meeting strong demand, Lim notes. Affin Hwang raises IHH's target price to MYR8.30 from MYR7.40, and maintains a buy rating given its earnings growth prospects and undemanding valuation. Shares are unchanged at MYR7.22. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
October 09, 2024 21:30 ET (01:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。